News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GeneData AG And Schering AG (SHR) Expand Genomics-based Drug Discovery Collaboration Worldwide

10/19/2005 5:09:40 PM

BASEL, Switzerland, Jan. 14 /PRNewswire/ -- Today, Genedata and Schering AG, Germany, a major German pharmaceutical company, announced that they are widening the scope of their four-year collaboration. In order to strengthen their global drug discovery program, Schering has extended the license for Expressionist(TM), the Genedata computational system for large-scale gene expression analysis in the pharmaceutical industry. Schering's move to implement Expressionist across several Schering sites validates the scalability of the software system as a platform for organization-wide data analysis. Under the terms of the agreement, Genedata will also provide consulting services to ensure the continued smooth integration of Expressionist into Schering's global research landscape.

"Since 1999, we have been partnering with Genedata. Therefore, we know from experience that Expressionist is the most comprehensive system for microarray data analysis, data management, and results management. To fully integrate their system into our drug discovery pipeline, we have initiated collaborations with Genedata in target identification, toxicology, and pharmacology. We are also joining forces to build a custom database system that will integrate our research results worldwide," says Dr. Hans-Dieter Pohlenz, Head of Genomics and Bioinformatics within Schering Research Center Europe.

"Schering's decision to implement Expressionist as a key element of their global research database demonstrates the trust they have in the technical and scientific capabilities of Expressionist. Expressionist will support their project-based, international research teams, but will also help them comply with the rigorous standards prescribed by regulatory agencies. We are looking forward to working closely with Schering on the scientific global implementation," states Dr. Andreas Hohn, Director of Business Development at Genedata.


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Genedata AG

CONTACT: Dr. Andreas Hohn, Director of Business Development, GenedataAG, +41-61-697-6700, or fax, +41-61-697-7244, or

Read at

comments powered by Disqus